Microba Life Sciences Limited (MAP.AX)
AUD 0.19
(0.0%)
AUD 0.19
(0.0%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 | -20.49 Million AUD | 37.53% |
| 2023 | -30.9 Million AUD | -5.64% |
| 2022 | -29.25 Million AUD | -129.28% |
| 2021 | -12.75 Million AUD | -101.46% |
| 2020 | -6.33 Million AUD | 40.19% |
| 2019 | -10.58 Million AUD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | -27.21 Million AUD | 6.97% |
| 2024 Q4 | -20.49 Million AUD | 0.0% |
| 2024 Q2 | -26.46 Million AUD | 2.76% |
| 2024 FY | -19.3 Million AUD | 37.53% |
| 2023 Q3 | -31.45 Million AUD | 22.85% |
| 2023 FY | -30.9 Million AUD | -5.64% |
| 2023 Q4 | -29.25 Million AUD | 6.98% |
| 2023 Q2 | -40.76 Million AUD | 1.44% |
| 2023 Q1 | -41.36 Million AUD | -40.4% |
| 2022 FY | -29.25 Million AUD | -129.28% |
| 2022 Q4 | -29.45 Million AUD | 0.92% |
| 2022 Q3 | -29.73 Million AUD | -228.22% |
| 2022 Q2 | -9.05 Million AUD | 3.89% |
| 2022 Q1 | -9.42 Million AUD | 26.13% |
| 2021 Q3 | -12.8 Million AUD | 0.0% |
| 2021 FY | -12.75 Million AUD | -101.46% |
| 2021 Q1 | 6.89 Million AUD | 0.0% |
| 2021 Q4 | -12.75 Million AUD | 0.34% |
| 2020 FY | -6.33 Million AUD | 40.19% |
| 2019 FY | -10.58 Million AUD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Australian Clinical Labs Limited | 282.76 Million AUD | 107.248% |
| BCAL Diagnostics Limited | -5.83 Million AUD | -251.428% |
| Genetic Signatures Limited | -35.03 Million AUD | 41.497% |
| Genetic Technologies Limited | -377.06 Thousand AUD | -5335.197% |
| Healius Limited | 1.53 Billion AUD | 101.333% |
| Imagion Biosystems Limited | 5.81 Million AUD | 452.661% |
| Integral Diagnostics Limited | 315.35 Million AUD | 106.499% |
| INOVIQ Ltd | -8.69 Million AUD | -135.615% |
| Monash IVF Group Limited | 48.23 Million AUD | 142.491% |
| Rhythm Biosciences Limited | -545.67 Thousand AUD | -3655.734% |
| Sonic Healthcare Limited | 3.87 Billion AUD | 100.53% |